Valuation
- Market cap
- 21,646,870,000
- Revenue TTM
- $3,247,010,000
- Net income TTM
- $-1,285,380,000
- P/E (trailing)
- 0.00
- P/E (forward)
- β
- Profit margin
- -39.59%
- Debt to equity
- 0.02
Trading
- Volume
- 844,800
- Avg volume
- 990,176
- Day's range
- $84.23 β $86.00
- Shares out
- 252,884,000
- Stochastic %K
- 19%
- Beta
- 1.28
- Analysts
- Moderate Buy
- Price target
- $117.89
Company profile
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast...
Show more
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 49 6131 9084
- Website
- https://www.biontech.de
- Address
- An der Goldgrube 12, Mainz, Germany
Latest news
No headlines yet.
Stocktwits
IndyOne
Nov 15, 10:49 PM
$GSK reached a cross-licensing agreement with Moderna resolving their COVID-19 vaccine patent dispute in Europe.
$MRNA
The pharma group secured a significant injunction against Pfizer-BioNTech covering liposome delivery technology used in RNA vaccines across multiple European markets.
$PFE
$BNTX
Bought on close, did not fade like I thought it would on Friday. Looks good for a run. πββοΈ πββοΈ πββοΈ
1 replies
Moniex
Nov 13, 7:33 PM
$BNTX Earnings won't send this but a major trial success will. Pumitamig is the most promising asset that could treat multiple cancers including pancreatic, colorectal, liver, NSCLC etc. Patience could earn great rewards here.
1 replies
taxplanr
Nov 13, 6:12 PM
Do you know what
$MRNA $BNTX and
$PFE really hate ...
a non pharma treatment for Long COVID / vaccine
look what they did to the stock since the announcement
0 replies
taxplanr
Nov 13, 2:41 PM
Have you heard of SADS?
$MRNA $PFE $BNTX
https://makisw.substack.com/p/breaking-news-57-year-old-drjennifer?utm_source=post-email-title&publication_id=1385328&post_id=224715550&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 replies
None_
Nov 13, 3:53 AM
$BNTX https://www.fiercepharma.com/pharma/biontech-pays-205m-fda-voucher-speed-late-stage-oncology-pipeline
0 replies
Rayvio_News_Filter
Nov 10, 12:11 PM
$SRRK Β·
$BNTX π€
Scholar Rock Holding Corporationβs subsidiary agreed to sell a Rare Pediatric Disease Priority Review Voucher to BioNTech SE for
$205 million in cash upon closing.
Actionable market event
0 replies